Metaprotereol Sulfate Inhalation Solution, 5%

Company
Morton Grove Pharmaceuticals

Approval Status
Approved March 1997

Treatment for
bronchial asthma and reversible bronchospasm

Areas
Respiratory

Metaprotereol Sulfate Inhalation Solution, 5% has been approved for the treatment of bronchial asthma and reversible bronchospasm. The product is also indicated for the treatment of acute asthmatic attacks in children over the age of six. Metaprotereol Sulfate Inhalation Solution, 5% was found to be therapeutically bioequivalent to the listed drug, Alupentr Inhalation Solution, 5% marketed by Boehringer Ingelheim Pharmaceuticals, Inc.

Metaprotereol Sulfate Inhalation Solution, 5% Drug Information

The Metaprotereol Sulfate Inhalation Solution, 5% drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top